Study of SU011248 in Patients With Advanced Kidney Cancer
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To determine the objective tumor response of single-agent SU011248 at a dose of 50 mg orally
once daily for 4 consecutive weeks and 2 weeks rest, repeated every 6 weeks in patients with
metastatic Renal Cell Cancer (RCC).